FDA reviewing Aerie's resubmitted NDA

By Becky Simon | May 15, 2017 | 10:12 PM GMT

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) said FDA accepted for review its resubmitted NDA for Rhopressa netarsudil ophthalmic solution 0.02%

Read the full 188 word article

How to gain access

Continue reading with a
two-week free trial.